Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid.
Packer
Sharon
S
Berman
Stephen A
SA
D000081:Acetamides / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D000328:Adult; D000890:Anti-Infective Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D003511:Cyclohexanols / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D003865:Major Depressive Disorder / Q000188:drug therapy; D004347:Drug Interactions; D005260:Female; D006801:Humans; D000069349:Linezolid; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D023303:Oxazolidinones / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D020230:Serotonin Syndrome / Q000139:chemically induced*; D000069470:Venlafaxine Hydrochloride
D000081:Acetamides; D000890:Anti-Infective Agents; D003511:Cyclohexanols; D008996:Monoamine Oxidase Inhibitors; D023303:Oxazolidinones; D000069470:Venlafaxine Hydrochloride; D000069349:Linezolid